European Breast Biopsy Devices Industry

• Publication date: February 2010

This report analyzes the European market for Breast Biopsy Devices in US$ Million. Annual Forecasts are provided for the period 2007 through 2015. Also, a six-year historic analysis is provided for the market. The report profiles 25 companies including many key and niche players such as C. R. Bard Inc., Bard Biopsy Systems, Cardinal Health, Inc., Ethicon Endo-Surgery, Inc., GE Healthcare, Hologic, Inc., iCAD, Inc., Intact Medical Corporation, Ko...

This report analyzes the European market for Breast Biopsy Devices in US$ Million. Annual Forecasts are provided for the period 2007 through 2015. Also, a six-year historic analysis is provided for the market. The report profiles 25 companies including many key and niche players such as C. R. Bard Inc., Bard Biopsy Systems, Cardinal Health, Inc., Ethicon Endo-Surgery, Inc., GE Healthcare, Hologic, Inc., iCAD, Inc., Intact Medical Corporation, Koninklijke Philips Electronics N.V., Rubicor Medical, Inc., Sanarus Technologies, SenoRx, Inc., and Siemens AG. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Diagnostics Industry in Germany

BREAST BIOPSY DEVICES MCP-6018
A EUROPEAN MARKET REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3


II. A EUROPEAN MARKET REPORT

1. INDUSTRY OVERVIEW II-1
A Prelude II-1
Market Opportunity II-1
Breast Cancer: A Common Malignancy Among Females in the
Western World II-1
Increased Instances of Breast Cancer in Younger Women! II-2
European Biopsy Devices Market II-2
Widespread Adoption of Advanced Diagnostic Systems Will
Increase Demand for Breast Biopsy Devices II-2
Key Statistics: II-3
Table 1: Worldwide Breast Cancer Incidence Rates & Mortality
Rate (Per 100,000 persons) for the year 2007 (includes
corresponding Graph/Chart) II-3

Table 2: Percentage of Five-Year Survival Rate For Breast
Cancer by Cancer Stage (includes corresponding Graph/Chart) II-4
Competitive Scenario: II-4
Current Market Conditions II-4
Impact of Recession II-4
Key Market Trends & Issues: A Review II-5
Continuous Fight Against Cancer: A Key Propeller for Growth II-5
Population Aging Makes Rise Of Cancer Diagnostics Inevitable II-5
Table 3: Probability of Developing Breast Cancer by Age
Group II-6

Table 4: Probability of Surviving Breast Cancer by Age
Group (includes corresponding Graph/Chart) II-6

Table 5: Population Over 65 Years and Above in North
America, Western Europe and Eastern Europe for the year
2007 (In Millions) (includes corresponding Graph/Chart) II-7
Promising Developments in Breast Cancer Diagnosis Underway II-7
Needle Biopsy Score Over Open Biopsy II-8
Widespread Awareness Among Patients & Practitioners: The
Need of the Hour II-8
Rise in Use of Breast Markers II-8
Rise in Use of MRI Guided Breast Biopsy II-9
Government Breast Cancer Screening Programs Drive Biopsy
Devices Market II-9
Rise in Use of Single Insertion Breast Biopsy Needle II-9
Roll Out of Integrated Breast Centers II-10
Vacuum-Assisted Biopsy Gain Physician Preference II-10
Table 6: Reimbursement Benefits for Vacuum-Assisted Over
Core Needle Biopsy in Office Based Setting in the US Market
for the year 2007 II-11
Reimbursement & Price Sensitivity: Key Challenges for Breast
Biopsy Market II-11
Susceptibility to Radiation Exposure May Hinder Growth II-11
Competing Solutions May Limit Need of Breast Biopsy Procedures II-12
High Costs of Biopsy Markers May Constrain Growth II-12
Pricing Factors II-12
Technology Innovations in Breast Care Management: II-12
Breast Thermography - An Alternative to Mammography II-12
Advanced MRI Technique May Limit Breast Biopsies in Women II-13
Identification of New Genes May Improve Breast Cancer Diagnosis II-14
Innovative MRI Technique Identifies Cancerous Breast Tumors II-14

2. REGIONAL PERSPECTIVE II-15
Europe II-15
Market Overview II-15
Changing Physician Preferences Shape Breast Biopsy Market II-15
Market Restraints II-15
Key Statistics: II-16
Table 7: Top Three Cancers Among Europeans for the year 2006
(includes corresponding Graph/Chart) II-16

Table 8: European Age-Standardised Rate (ASR) for Breast
Cancer Incidence per 100, 000 Individuals, By Country, for
the year 2006 (includes corresponding Graph/Chart) II-17

Table 9: European Age-Standardised Rate (ASR) for Breast
Cancer Mortality per 100, 000 Individuals, By Country, for
the year 2006 (includes corresponding Graph/Chart) II-18
Germany II-18
Italy II-19
Table 10: Female Breast Cancer Cases in Italy (2005):
Breakdown of Mortality, Incidence and Prevalence by Number
of Cases for Key Italian Regions (includes corresponding
Graph/Chart) II-19
United Kingdom II-20
Role of Government II-20
Key Statistics: II-20
Table 11: Percentage Share Breakdown of Common Causes of
Female Cancer Deaths in the UK for the year 2007 (includes
corresponding Graph/Chart) II-20

Table 12: Breakdown of New Breast Cancer Cases Diagnosed in
the UK by Gender for the year 2006 (includes corresponding
Graph/Chart) II-21

Table 13: Breakdown of Breast Cancer Mortality in the UK by
Gender for the year 2007 (includes corresponding
Graph/Chart) II-21
Other Western Nations: Facts & Figures II-22
United States II-22
Key Statistics: II-22
Table 14: Breast Cancer in the United States: Breakdown of
Incidence Rate By Ethnic Group for the year 2007 II-22

Table 15: Breast Cancer in the United States: Breakdown of
Mortality Rate By Ethnic Group for the year 2007 II-23

Table 16: Breakdown of Number of Breast Biopsy Procedures
in the United States for the Years 2008 & 2013 (Number of
Procedures in 000s) (includes corresponding Graph/Chart) II-23

Table 17: US Breast Biopsy Devices Market (2008): Percentage
Share Breakdown of Revenues by Key Players (includes
corresponding Graph/Chart) II-23

Table 18: US Vaccuum-Assisted Breast Biopsy Disposables
Market (2007): Percentage Share Breakdown of Revenues by
Key Players (includes corresponding Graph/Chart) II-24

Table 19: US Vaccuum-Assisted Biopsy Procedures (2007):
Percentage Share Breakdown by Procedures Type (includes
corresponding Graph/Chart) II-24

Table 20: US Biopsy Products Market (2008): Percentage Share
Breakdown of Revenues by Product Segment (includes
corresponding Graph/Chart) II-25
Canada II-25
Table 21: New Breast Cancer-Related Diagnosis in Canada
(2007): Percentage Share Breakdown of Female Breast Cancer
Incidence by Age Group (includes corresponding Graph/Chart) II-25

Table 22: Breast Cancer-Related Deaths in Canada (2007):
Percentage Share Breakdown of Female Breast Cancer Related
Death by Age Group (includes corresponding Graph/Chart) II-25

3. PRODUCT OVERVIEW II-26
Breast Cancer II-26
Risk Factors II-26
Breast Cancer Screening II-26
Breast Cancer Diagnosis II-27
Breast Biopsy II-27
Breast Biopsy Procedures II-28
Surgical Biopsy II-29
Needle Biopsy II-29
Fine Needle Aspiration II-29
Core Needle Biopsy II-30
Vacuum-Assisted Biopsy II-30
Commonly Used Breast Biopsy Devices II-30
Spring Loaded Biopsy Needle II-30
Vacuum-Assisted Core Biopsy Device II-30
Minimally Invasive Breast Biopsy (MIBB) Device II-31
Advanced Breast Biopsy Instrumentation (ABBI) Device II-31
Mammotome II-31
Advances in Breast Imaging Techniques II-31
Ultrasound Image Guidance II-32
Stereotactic Image Guidance II-32
Magnetic Resonance Imaging II-32
Mammotome® Breast Biopsy System II-33
Digital Spot-View Mammography Enhances Breast Biopsy II-33
Biopsy Tissue Markers II-33

4. PRODUCT INNOVATIONS/INTRODUCTIONS II-34
Senorx Unveils New Model of Senosonix System II-34
SenoRx to Release StarchMark™ II-34
SenoRx Unveils EnCor® II-34
Siemens Healthcare Launches New Biopsy Device II-34

5. RECENT INDUSTRY ACTIVITY II-35
Terason Enters into Agreement with SenoRx II-35
SenoRx Receives CE Mark Rights for Contura™ MLB II-35
RevMed Inks a Global License with SPD II-35
Sanarus Technologies Acquires Sanarus Medical II-36
Hologic Obtains CE Mark Approval for Celero® II-36
Echoserve, SenoRx Enter Into Co-Promotion Deal II-36
Naviscan Receives FDA’s Approval for Stereo Navigator™ II-36
Volcano Acquires Novelis II-37
SenoRx Receives CE Mark Approval for SenoSonix II-37
Hologic Completes Merger with Cytyc Corporation II-37

6. FOCUS ON SELECT PLAYERS II-38
C. R. Bard Inc. (USA) II-38
Bard Biopsy Systems (USA) II-38
Cardinal Health, Inc. (USA) II-38
Ethicon Endo-Surgery, Inc (USA) II-39
GE Healthcare (UK) II-39
Hologic, Inc. (USA) II-39
iCAD, Inc. (USA) II-40
Intact Medical Corporation (USA) II-40
Koninklijke Philips Electronics N.V. (The Netherlands) II-40
Rubicor Medical, Inc., (USA) II-41
Sanarus Technologies, LLC (USA) II-41
SenoRx, Inc (USA) II-41
Siemens AG (Germany) II-41

7. GLOBAL MARKET PERSPECTIVE II-42
Table 23: European Recent Past, Current & Future Analysis for
Breast Biopsy Devices with Annual Sales Figures in US$ Million
for Years 2007 through 2015 (includes corresponding
Graph/Chart) II-42

Table 24: European Historic Review for Breast Biopsy Devices
with Annual Sales Figures in US$ Million for Years 2001
through 2006 (includes corresponding Graph/Chart) II-42


III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 25 (including Divisions/Subsidiaries - 31)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 19
Japan 1
Europe 11
Germany 3
The United Kingdom 2
Italy 2
Rest of Europe 3
Middle-East 1
------------------------------------------